TORONTO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- GeneNews Limited ("GeneNews"or the "Company") (TSX:GEN) today announced the appointment of Joel V. Brill, MD as the Chief Medical Officer of its Innovative Diagnostic Laboratory, LLP ("IDL") joint-venture. In his new role, Dr. Brill will assume leadership responsibility for the medical aspects of IDL's laboratory, and act as the Company's medical lead with physicians, patients and insurance providers. Dr. Brill will serve on IDL's executive committee as its medical representative, providing strategic counsel on current and new products, the identification of new technologies, and reimbursement issues.
Dr. Brill is an executive clinician with 30 years of experience providing strategic leadership and medical oversight to data-driven health organizations, skilled in strategy, development and implementation of innovative health programs, products and payment systems, with extensive experience in clinical practice and research. He has held management positions with several companies including Predictive Health LLC, Blue Shield of California and Prudential Healthcare, and is a member of editorial advisory boards for multiple journals. Dr. Brill is a nationally recognized expert on quality improvement, value-based care, coverage and reimbursement.
Board Certified in Internal Medicine and Gastroenterology, Dr. Brill graduated from the Rosalind Franklin University of Medicine and Science – Chicago Medical School. He completed his internship and residency in Internal Medicine at the UCLA San Fernando Valley Program, and a fellowship in Gastroenterology at Los Angeles Country – USC Medical Center. Dr. Brill also completed the Management Program for Health Care Organizations at the UCLA School of Public Health.
"It is with great pleasure that we welcome the distinguished career and clinical experience that Dr. Brill brings to IDL," commented GeneNews Executive Chairman, James R. Howard-Tripp. "IDL was established to provide physicians and their patients with an expanding menu of advanced tests to aid in early cancer detection. Joel's executive-level experience, combined with his vision and technical background, make him the ideal clinician to oversee the delivery of these services, while supporting IDL's strategy to help physicians improve patient care."
"I look forward to joining the IDL team during such an exciting time in its history," said Dr. Brill. "IDL has made great strides this past year in building its business and expanding its menu of proprietary cancer tests, and I am excited by this opportunity to help the organization continue on its strong growth trajectory."
GeneNews is focused on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a primary focus on cancer-related indications. The Company's lead product, ColonSentry®, is the world's first blood test to assess an individual's current risk for colorectal cancer. In 2013, GeneNews created a U.S. joint venture, Innovative Diagnostic Laboratory, LLP ("IDL"), that it is committed to help become a leader in molecular diagnostics and personalized medicine, serving as a strong commercialization outlet for advanced cancer tests. Taking a multi-view approach to the diagnosis and treatment of cancer, IDL is working to assemble, through a combination of internal pipeline development, third-party licenses and potential acquisitions, a robust menu of novel, proprietary tests to be offered by it throughout the United States. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com and www.MyInnovativeLab.com, respectively.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events, including with respect to the Company's ability to raise capital and complete the Private Placement when anticipated. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein including as a result of a change in the trading price of the Common Shares, the TSX not approving the transaction, or the Company being unable to find purchasers for its Units. Investors should consult the Company's ongoing quarterly filings, annual information form and annual reports for additional information on risks and uncertainties relating to these forward- looking statements. The reader is cautioned not to rely on these forward-looking statements. Subject to applicable law, the Company disclaims any obligation to update these forward-looking statements.
CONTACT: Company Contact: James R. Howard-Tripp Executive Chairman Office: (905) 209-2030 email@example.com Investor & Media Contact: Stephen Kilmer Office: (646) 274-3580 Mobile: (905) 906-6908 firstname.lastname@example.org